ISRCTN40098615CompletedNot Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2008/2009-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations
Crucell, Berna Biotech Ltd (Switzerland)0 sites110 target enrollmentStarted: May 22, 2008Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 110
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Healthy female and male volunteers equal to or older than 18 years of age
- •2. Written informed consent
Exclusion Criteria
- •1. Pregnancy and lactation
- •2. Serious adverse reaction to any influenza vaccine
Investigators
Similar Trials
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsInfluenzaISRCTN89337058Crucell Switzerland AG (Switzerland)110
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsInfluenzaISRCTN30202688Crucell, Berna Biotech Ltd (Switzerland)110
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in children aged 6 to 35 months in comparison to a commercially available influenza vaccineRespiratoryInfluenza, virus not identifiedInfluenzaISRCTN10483274Berna Biotech Ltd, a Crucell Company (Switzerland)1,239
Completed
Phase 1
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
Not yet recruiting
Phase 1
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana